The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile
Drug Metabolism and Disposition · 2025-08 · 53 (8) · 100110
DOI: 10.1016/j.dmd.2025.100110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025-08. Verfasst von Eric T Gangl und 11 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts. Electronic address: eric.gangl@astrazeneca.com. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Azetidines, Isoquinolines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Camizestrant (AZD9833) is a potent, next-generation oral selective estrogen receptor (ERα) degrader (SERD) and complete ERα antagonist. It is currently being investigated in multiple Phase 3 clinical trials for the treatment of ER+/HER2-negative breast cancer. ER is a clinically validated target, and when camizestrant was progressed into the clinic, the only approved SERD was fulvestrant which is delivered via once-monthly intramuscular injections. Oral delivery of a SERD has proved challenging, often due to poor pharmacokinetic (PK) properties and/or short half-life (t½). Camizestrant is designed to overcome these challenges as a low molecular weight, low lipophilicity base with good permeability characteristics. It has extensive tissue distribution (Vd ss 6-13 L/kg) and high bioavailability in animals, yet dose dependent bioavailability (from 2 to >90%) in dog. The in vitro hepatic metabolic intrinsic clearance (CL int ) for camizestrant varied across species with CL int determined in human hepatocytes (530 μL/min/g liver) lower than rat (5900 μL/min/g liver) and dog (5000 μL/min/g liver). The K m determined in dog liver microsomes (0.3 μM) was lower compared to human (1 μM) and rat (6 μM). Cytochrome P450 (CYP) phenotyping studies determined metabolism in dog is primarily mediated by CYP2D15 whereas CYP3A4/5 are the dominant CYP isoforms in human. A PBPK model was developed and validated based on the integrated mechanistic data which recapitulated the observed dose dependent exposure in dog. Human exposures were simulated based on this model which incorporated human specific parameters and indicated that human clearance was independent of dose at pharmacologically relevant concentrations. The simulated human PK parameters and exposure profile(s) were appropriate for progression of camizestrant into Phase 1 clinical evaluation. Clinical exposure data confirmed the pre-clinical predictions and has enabled rapid exploration of ERα pharmacology in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DMPK, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts. Electronic address: eric.gangl@astrazeneca.com.
- DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology Safety Science, R&D, AstraZeneca, Cambridge, United Kingdom.
- DMPK, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts.
- Clinical Pharmacology Safety Science, AstraZeneca, Gothenburg, Sweden.
- Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Förderung
- AstraZeneca
Zitieren
APA
Gangl, E. T., Markandu, R., Sharma, P., Sykes, A., Pop-Damkov, P., Sarkar, U., Andersson, L., Morentin-Gutierrez, P., Scott, J. S., Fretland, A. J., Klinowska, T., & McGinnity, D. F. (2025). The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile. Drug Metabolism and Disposition, 53(8), 100110. https://doi.org/10.1016/j.dmd.2025.100110
Vancouver
Gangl ET, Markandu R, Sharma P, Sykes A, Pop-Damkov P, Sarkar U, et al. The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile. Drug Metabolism and Disposition. 2025;53(8):100110. doi:10.1016/j.dmd.2025.100110
BibTeX
@article{Gangl2025,
author = {Gangl, Eric T and Markandu, Roshini and Sharma, Pradeep and Sykes, Andy and Pop-Damkov, Petar and Sarkar, Ujjal and Andersson, Linda and Morentin-Gutierrez, Pablo and Scott, James S and Fretland, Adrian J and Klinowska, Teresa and McGinnity, Dermot F},
title = {The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile},
journal = {Drug Metabolism and Disposition},
year = {2025},
volume = {53},
number = {8},
pages = {100110},
doi = {10.1016/j.dmd.2025.100110}
}
EUVIMED